Memphis-based Methodist Le Bonheur Healthcare to cut 161 jobs as part of restructuring
Methodist Le Bonheur Healthcare said its Planning, Alignment, Transformation and High (PATH) performance initiative will streamline the health network's staff and patient services.
With the operational change, Methodist said 161 employees will be affected, approximately 1% of the company's workforce. Staff impacted by the layoffs who cannot find new roles within Methodist's healthcare network will be offered severance pay and career transition support, according to a news release.
'As part of our mission to serve the entire community, we regularly examine our service offerings and processes to ensure that they align with community needs and follow best clinical practices in a rapidly changing healthcare environment,' Methodist Le Bonheur Healthcare CEO and President Michael Ugwueke said in a statement.
BUSINESS NEWS: FedEx to cut 480+ jobs, close facilities as part of Network 2.0 restructuring
On Aug. 1, Methodist will consolidate its obstetric service wing (labor and delivery) at Methodist South Hospital, located at 1300 Wesley Drive in Whitehaven, with existing operations at Methodist Le Bonheur's Germantown and Olive Branch hospitals.
'These changes align with our goal of maintaining long-term strength and high-quality services,' Methodist Le Bonheur Healthcare Executive Vice President and Chief Operating Officer Monica Wharton said in a statement.
Neil Strebig is a journalist with The Commercial Appeal. He can be reached at neil.strebig@commercialappeal.com, 901-426-0679 or via X/Twitter: @neilStrebig.
This article originally appeared on Memphis Commercial Appeal: Methodist Le Bonheur Healthcare announces layoffs and restructuring
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
McKesson's (NYSE:MCK) Q2 Sales Top Estimates
Healthcare distributor and services company McKesson (NYSE:MCK) announced better-than-expected revenue in Q2 CY2025, with sales up 23.4% year on year to $97.83 billion. Its non-GAAP profit of $8.26 per share was 1.4% above analysts' consensus estimates. Is now the time to buy McKesson? Find out in our full research report. McKesson (MCK) Q2 CY2025 Highlights: Revenue: $97.83 billion vs analyst estimates of $96.48 billion (23.4% year-on-year growth, 1.4% beat) Adjusted EPS: $8.26 vs analyst estimates of $8.15 (1.4% beat) Management slightly raised its full-year Adjusted EPS guidance to $37.50 at the midpoint Operating Margin: 1.1%, in line with the same quarter last year Free Cash Flow was -$1.11 billion compared to -$1.55 billion in the same quarter last year Market Capitalization: $88.76 billion Company Overview With roots dating back to 1833, making it one of America's oldest continuously operating businesses, McKesson (NYSE:MCK) is a healthcare services company that distributes pharmaceuticals, medical supplies, and provides technology solutions to pharmacies, hospitals, and healthcare providers. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, McKesson grew its sales at a decent 10.3% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. McKesson's annualized revenue growth of 15.3% over the last two years is above its five-year trend, suggesting its demand recently accelerated. We can better understand the company's revenue dynamics by analyzing its most important segment, U.S. Pharmaceutical . Over the last two years, McKesson's U.S. Pharmaceutical revenue averaged 17.6% year-on-year growth. This quarter, McKesson reported robust year-on-year revenue growth of 23.4%, and its $97.83 billion of revenue topped Wall Street estimates by 1.4%. Looking ahead, sell-side analysts expect revenue to grow 10% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is attractive given its scale and implies the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin McKesson was roughly breakeven when averaging the last five years of quarterly operating profits, lousy for a healthcare business. On the plus side, McKesson's operating margin rose by 3.3 percentage points over the last five years, as its sales growth gave it operating leverage. In Q2, McKesson generated an operating margin profit margin of 1.1%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. McKesson's EPS grew at an astounding 18.3% compounded annual growth rate over the last five years, higher than its 10.3% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into the nuances of McKesson's earnings can give us a better understanding of its performance. As we mentioned earlier, McKesson's operating margin was flat this quarter but expanded by 3.3 percentage points over the last five years. On top of that, its share count shrank by 23.1%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. In Q2, McKesson reported adjusted EPS at $8.26, up from $7.88 in the same quarter last year. This print beat analysts' estimates by 1.4%. Over the next 12 months, Wall Street expects McKesson's full-year EPS of $33.48 to grow 15.5%. Key Takeaways from McKesson's Q2 Results It was good to see McKesson narrowly top analysts' revenue and EPS expectations this quarter. The market seemed to be hoping for more, and the stock traded down 1.8% to $692 immediately following the results. So do we think McKesson is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
an hour ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores
Yahoo
an hour ago
- Yahoo
Retiree health care costs are climbing: What advisors need to know
Health care costs for retirees just keep rising. A 65-year-old retiring in 2025 can expect to spend $172,500 on health care costs and medical expenses throughout retirement, according to a new survey from Fidelity. Financial advisors say ignoring that number can be a costly decision for retirees. Since Fidelity began tracking retiree health care costs in 2002 — when the estimated expense for a 65-year-old was just $80,000 — projected costs have steadily climbed, far outpacing inflation. In the past year alone, Fidelity reported a 4% increase in total expected health care spending for retirees. READ MORE: A health care planning checklist for financial advisorsLong-term care costs can derail retirement plans. Here's how to manage themWhy protecting wealth starts with planning for health careSocial Security is changing — here's how advisors are preparing The estimate includes out-of-pocket prescription drug costs, Medicare premiums and other medical expenses, such as co-payments and deductibles. Researchers did not include potential costs from other health care-related expenses, including over-the-counter medications, most dental services and long-term care. Many retirees have found themselves ill-equipped to handle those costs, according to Shams Talib, head of Fidelity Workplace Consulting. "Year after year, so many Americans underestimate how much they'll need to save to cover health care costs in retirement," Talib said. "We recognize the impact health care costs can have on retirement savings. With the right tools and guidance, pre-retirees and retirees alike can take greater control of their financial futures by beginning the planning process as soon as possible." Clearing up Medicare misconceptions Financial advisors say one of the biggest impediments to planning for health care costs in retirement is a misconception about the role of Medicare. Namely, that it will cover more medical expenses than it does. "When I have these conversations with clients, especially those who are unprepared, the first step is just helping them slow down," said Melissa Cox, owner of Future-Focused Wealth in Dallas, Texas. "There's often a mix of embarrassment and fear. Many say, 'I didn't know this was something I needed to think about.' We walk through Medicare together, clarify what's covered and what isn't, and start looking at how their current financial picture can support a more realistic health care forecast." That picture can start to look very different depending on how short they are of covering estimated medical expenses. "Sometimes we have to pivot, adjust spending, reframe goals or revisit timelines, but that's okay," Cox said. "What matters most is giving people a sense of control over something that felt out of reach." Encourage clients to plan early Preparing for health care costs in retirement can be a relatively straightforward process as long as clients start early, advisors say. Near-retirees have several cost-effective options to help cover expenses, including Medigap, long-term care insurance and life insurance with care-related riders. But for older retirees seeking coverage later, the process becomes more complex and often more expensive. According to Andrew Crowell, vice chairman of wealth management for D.A. Davidson in New York City, waiting too long to sign up for certain plans can make them difficult to obtain at all. "I've had some clients recently, in good health but in their 70s, who were looking for a little extra coverage. … Both of them [were] denied coverage because they couldn't pass a cognition test," Crowell said. "I have perfectly lucid conversations with them all the time, but the test that they were given was an individual over the phone reading a long list of words, and then they were asked to repeat back as many of the words they remembered hearing in the short space, and they froze up. They stammered through a few of them, and the insurance just denied them on that, and they have no aches, no pains, no typical aging stuff." If those same clients had tried to sign up for policies in their 50s or 60s, the situation would have looked very different, Crowell said. "If we had done that in their 60s or in their 50s — young, healthy — they would have qualified for a great preferred rate premium, and it wouldn't be an issue," he said. "Now they can try to reapply, but you know they're going to have the jitters from the minute they reapply, and they're probably going to freeze up again just because of that." Crowell, who has been working in the industry for over 30 years, said insurance companies are becoming more cautious when assessing people due to increasing longevity. When it's too late to start early Starting early is one of the most effective strategies in financial planning — and health care planning is no exception. But even for clients who come to an advisor later in life, there are still viable options to manage rising medical costs. "When I work with clients who are unprepared for these costs, the conversation often shifts to what they value most in their retirement plan," said Beau Kemp, a financial advisor at SwitchPoint Financial Planning in Lehi, Utah. "If the plan goes from looking good to looking constrained with the increased health care costs, we have to make some adjustments." Exactly what those adjustments look like depends on the client's lifestyle preferences, Kemp said. Clients set on maintaining their current lifestyle may need to delay retirement as they build up their savings. Others who are more concerned with retiring at a specific age may have to scale back their spending to make room for medical costs. "I rarely decrease the projected medical expenses in a plan because these costs are largely out of our control," Kemp said. "The focus needs to be on what we can control and if a client is comfortable with those adjustments. The goal is to create a plan that provides both financial security and peace of mind."
